Kalaris Therapeutics, Inc. (KLRS)
3.88
-0.06
(-1.52%)
USD |
NASDAQ |
Sep 04, 11:29
Kalaris Therapeutics Cash from Investing (Quarterly) : 20.17M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 20.17M |
| March 31, 2026 | -50.35M |
| December 31, 2025 | 14.98M |
| September 30, 2025 | -34.71M |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 25.22M |
| September 30, 2023 | -66.85M |
| June 30, 2023 | 37.89M |
| March 31, 2023 | 41.72M |
| December 31, 2022 | 13.54M |
| Date | Value |
|---|---|
| September 30, 2022 | -38.56M |
| June 30, 2022 | -0.479M |
| March 31, 2022 | -54.98M |
| December 31, 2021 | -13.52M |
| September 30, 2021 | 54.97M |
| June 30, 2021 | 79.71M |
| March 31, 2021 | 64.83M |
| December 31, 2020 | 1.922M |
| September 30, 2020 | -210.26M |
| June 30, 2020 | 25.00M |
| March 31, 2020 | 13.84M |
| December 31, 2019 | 34.88M |
| September 30, 2019 | 0.046M |
| June 30, 2019 | -99.57M |
| March 31, 2019 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Replimune Group, Inc. | 49.99M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
| Sarepta Therapeutics, Inc. | -93.37M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -11.43M |
| Cash from Financing (Quarterly) | 0.01M |
| Free Cash Flow | -45.63M |
| Free Cash Flow Per Share (Quarterly) | -0.4804 |
| Free Cash Flow to Equity (Quarterly) | -11.42M |
| Free Cash Flow to Firm (Quarterly) | -11.43M |
| Free Cash Flow Yield | -52.78% |